2,013 Shares in Revvity, Inc. (NYSE:RVTY) Bought by Prentiss Smith & Co. Inc.

Prentiss Smith & Co. Inc. bought a new position in shares of Revvity, Inc. (NYSE:RVTY) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 2,013 shares of the company’s stock, valued at approximately $220,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Byrne Asset Management LLC bought a new position in Revvity during the fourth quarter worth $1,112,000. State of Michigan Retirement System bought a new position in shares of Revvity in the fourth quarter valued at $3,688,000. Gulf International Bank UK Ltd bought a new position in shares of Revvity in the fourth quarter valued at $1,136,000. State of Alaska Department of Revenue bought a new position in shares of Revvity in the fourth quarter valued at $1,456,000. Finally, International Assets Investment Management LLC bought a new position in shares of Revvity in the fourth quarter valued at $1,278,000. 86.65% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on RVTY shares. Barclays raised their price objective on shares of Revvity from $92.00 to $105.00 and gave the company an “equal weight” rating in a research note on Thursday, January 25th. Stifel Nicolaus raised their price objective on shares of Revvity from $95.00 to $110.00 and gave the company a “hold” rating in a research note on Friday, February 2nd. KeyCorp raised their price target on shares of Revvity from $110.00 to $126.00 and gave the company an “overweight” rating in a research report on Friday, February 2nd. UBS Group lowered shares of Revvity from a “buy” rating to a “neutral” rating and raised their price target for the company from $105.00 to $125.00 in a research report on Tuesday, January 16th. Finally, Evercore ISI raised shares of Revvity from an “in-line” rating to an “outperform” rating and raised their price target for the company from $88.00 to $125.00 in a research report on Thursday, January 4th. Six analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, Revvity has an average rating of “Moderate Buy” and a consensus price target of $118.91.

Revvity Stock Performance

NYSE RVTY traded down $0.59 during trading hours on Thursday, reaching $102.09. 461,111 shares of the company were exchanged, compared to its average volume of 849,016. Revvity, Inc. has a 1 year low of $79.50 and a 1 year high of $132.54. The business’s 50 day simple moving average is $104.72 and its 200-day simple moving average is $101.50. The company has a quick ratio of 1.77, a current ratio of 2.07 and a debt-to-equity ratio of 0.40. The stock has a market capitalization of $12.61 billion, a P/E ratio of 18.56, a P/E/G ratio of 2.69 and a beta of 1.09.

Revvity (NYSE:RVTY) last posted its quarterly earnings data on Thursday, February 1st. The company reported $1.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.15 by $0.10. Revvity had a net margin of 25.20% and a return on equity of 7.41%. The business had revenue of $695.90 million during the quarter. On average, equities research analysts expect that Revvity, Inc. will post 4.65 earnings per share for the current year.

Revvity Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 9th. Stockholders of record on Friday, July 19th will be paid a $0.07 dividend. This represents a $0.28 annualized dividend and a dividend yield of 0.27%. Revvity’s payout ratio is 5.09%.

Insider Transactions at Revvity

In other news, insider Prahlad R. Singh sold 21,217 shares of Revvity stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $104.28, for a total value of $2,212,508.76. Following the completion of the transaction, the insider now owns 92,801 shares in the company, valued at $9,677,288.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.60% of the company’s stock.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.